Articles published by Biomea Fusion, Inc.
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
October 01, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
September 26, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
April 01, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
April 01, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
January 08, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
December 05, 2023
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA
Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023
November 02, 2023
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
October 30, 2023
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.